{
  "id": "e1ddfe452f968686",
  "title": "Press Release : Sanofi rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia",
  "description": "20260209T071500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2026/02/09/tmt-newswire/globenewswire/press-release-sanofis-rilzabrutinib-designated-breakthrough-therapy-in-the-us-and-orphan-drug-in-japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia/2274044",
  "published_at": "20260209T071500Z",
  "fetched_at": "2026-02-10T00:34:54.529614+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2026/02/09/tmt-newswire/globenewswire/press-release-sanofis-rilzabrutinib-designated-breakthrough-therapy-in-the-us-and-orphan-drug-in-japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia/2274044",
    "url_mobile": "https://www.manilatimes.net/2026/02/09/tmt-newswire/globenewswire/press-release-sanofis-rilzabrutinib-designated-breakthrough-therapy-in-the-us-and-orphan-drug-in-japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia/2274044/amp",
    "title": "Press Release : Sanofi rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia",
    "seendate": "20260209T071500Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2026/02/09/929807.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}